215 related articles for article (PubMed ID: 18416068)
1. [Assessment of mucosal injury in stage T1-T2NOMO bladder cancer after radiation or intravesical chemotherapy].
Kaprin AD; Panyshin GA; Garmash SV; Kostin AA; Khmelevskiĭ EV; Elagin VO
Vopr Onkol; 2008; 54(1):98-101. PubMed ID: 18416068
[TBL] [Abstract][Full Text] [Related]
2. [An evaluation of damage caused by radiation and chemical drugs to urinary bladder mucosa in stage T1-T2N0V0 cancer].
Kaprin AD; Pan'shin GA; Garmash SV; Kostin AA; Khmelevskiĭ EV; Elagin VO
Vopr Onkol; 2007; 53(4):473-6. PubMed ID: 17969414
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
Engeler DS; Wyler S; Neyer M; Hobi C; Müller J; Schmid HP
Scand J Urol Nephrol; 2008; 42(6):522-7. PubMed ID: 18609290
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary results of selective combined therapy for patients with urinary bladder cancer].
Zharinov GM; Agafonova MV; Tarazov PG; Suvorova IuV; Kozlov AA
Vopr Onkol; 2003; 49(5):636-8. PubMed ID: 14682138
[TBL] [Abstract][Full Text] [Related]
6. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
7. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
[TBL] [Abstract][Full Text] [Related]
8. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
[TBL] [Abstract][Full Text] [Related]
9. Optimal timing of radical cystectomy for patients with T1 bladder cancer.
Bochner BH
Urol Oncol; 2009; 27(3):329-31. PubMed ID: 19414124
[TBL] [Abstract][Full Text] [Related]
10. [Alternating radiochemotherapy in bladder carcinomas].
Dunst J
Strahlenther Onkol; 1998 Jun; 174(6):335-6. PubMed ID: 9645218
[No Abstract] [Full Text] [Related]
11. [Bladder wall permeability to to topically administered cisplatin].
Zyrianov BN; Selivanov SP
Urologiia; 2000; (5):28-30. PubMed ID: 11392221
[TBL] [Abstract][Full Text] [Related]
12. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer.
Hendricksen K; Gleason D; Young JM; Saltzstein D; Gershman A; Lerner S; Witjes JA
J Urol; 2008 Jul; 180(1):116-20. PubMed ID: 18485407
[TBL] [Abstract][Full Text] [Related]
13. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
14. Re: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.
Stewart AB; Mostafid H
J Urol; 2005 Apr; 173(4):1433; author reply 1433. PubMed ID: 15758827
[No Abstract] [Full Text] [Related]
15. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
16. [Results and prospects of the combined and complex treatment of cancer of the bladder].
Dunchik VN; Kariakin OB
Vestn Akad Med Nauk SSSR; 1988; (6):44-50. PubMed ID: 3213197
[No Abstract] [Full Text] [Related]
17. Treating bladder cancer: new methods, new management.
Moore S; Newton M; Grant EG; Keetch DW
Am J Nurs; 1993 May; 93(5):32-9. PubMed ID: 8488900
[No Abstract] [Full Text] [Related]
18. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with intravesical chemotherapy of deep bladder tumors responding to radiotherapy, decreasing their staging].
Rodríguez Alvarez J; Rodríguez Molina J; Rodríguez Betancour F; Resel Estévez L
Actas Urol Esp; 1987; 11(4):389-94. PubMed ID: 3318280
[No Abstract] [Full Text] [Related]
20. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
